Eisai Pipeline

Chugai Pharmaceutical's own in-house development pipeline has one of the strongest line-ups in Ja...

Description/ Summary: Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antib...

Inheriting the research from the parent company – Chugai Technos Corporation in Japan, we would l...

Chugai Pharmaceutical experienced unexpected demand for the drug Actemra during the pandemic, but...

Chugai Pharmaceutical Co Ltd Pipeline Drugs - GlobalData. ... Pipeline Drugs is one of the primar...